Expert review of clinical immunology · 2026
Drug development in systemic sclerosis: novel therapeutics to watch.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Batani Veronica, Colic Jelena, Scaletti Cristina, Molteni Raffaella, De Luca Giacomo, Bandini Giulia, Dagna Lorenzo, Annunziato Francesco, Matucci-Cerinic Marco, Campochiaro Corrado
Аннотация
INTRODUCTION: Systemic sclerosis (SSc) is increasingly understood as a triad of immune dysregulation, progressive fibrosis, and vasculopathy that evolve in parallel. The literature search was conducted using PubMed/MEDLINE, ClinicalTrials.gov, and the European Clinical Trials Database (EudraCT), including studies published in English up to October 2025.
AREAS COVERED: This review summarizes the most recent therapeutic strategies now in clinical development and links each to its underpinning pre‑clinical and translational evidence, thereby mapping how mechanistic insights are reshaping drug pipeline in SSc.
EXPERT OPINION: A key breakthrough is the emergence of cell‑based immunotherapies, bispecific antibodies, and next‑generation small molecules that extend beyond adaptive immune targets to modulate innate immunity directly. Collectively, these agents illustrate a unifying concept: successful disease modification will require the synchronous interception of inflammation, fibrotic remodeling, and vascular injury rather than approaching these domains independently.
AREAS COVERED: This review summarizes the most recent therapeutic strategies now in clinical development and links each to its underpinning pre‑clinical and translational evidence, thereby mapping how mechanistic insights are reshaping drug pipeline in SSc.
EXPERT OPINION: A key breakthrough is the emergence of cell‑based immunotherapies, bispecific antibodies, and next‑generation small molecules that extend beyond adaptive immune targets to modulate innate immunity directly. Collectively, these agents illustrate a unifying concept: successful disease modification will require the synchronous interception of inflammation, fibrotic remodeling, and vascular injury rather than approaching these domains independently.